In Vitro‐to‐In Vivo Extrapolation of Transporter Inhibition Data for Drugs Approved by the US Food and Drug Administration in 2018

@article{Yu2020InVV,
  title={In Vitro‐to‐In Vivo Extrapolation of Transporter Inhibition Data for Drugs Approved by the US Food and Drug Administration in 2018},
  author={J. Yu and I. Ragueneau-Majlessi},
  journal={Clinical and Translational Science},
  year={2020},
  volume={13},
  pages={693 - 699}
}
A systematic analysis of the inhibition transporter data available in New Drug Applications of drugs approved by the US Food and Drug Administration (FDA) in 2018 (N = 42) was performed. In vitro‐to‐in vivo predictions using basic models were available for the nine transporters currently recommended for evaluation. Overall, 29 parents and 16 metabolites showed in vitro inhibition of at least one transporter, with the largest number of drugs found to be inhibitors of P‐gp followed by BCRP. The… Expand
2 Citations

Topics from this paper

Assessing Transporter‐Mediated Natural Product‐Drug Interactions Via In vitro‐In Vivo Extrapolation: Clinical Evaluation With a Probe Cocktail
Hepatic transporter‐mediated pharmacokinetic drug–drug interactions: Recent studies and regulatory recommendations

References

SHOWING 1-10 OF 20 REFERENCES
The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2).
  • 513
  • PDF
Stiripentol (DIACOMIT) Labeling and clinical pharmacology biopharmaceutics review(s) (Drugs@FDA)
  • 2019
current status and contemporary issues
  • Adv. Drug Deliv. Rev. 116, 100–118
  • 2017
AKYNZEO) labeling and multi-discipline review/ summary, clinical, non-clinical (Drugs@FDA)
    BIKTARVY) labeling and multi-discipline review/summary, clinical, non-clinical (Drugs@FDA)
      Baricitinib (OLUMIANT) labeling and clinical pharmacology biopharmaceutics review(s) (Drugs@FDA)
        Doravirine (PIFELTRO) labeling and clinical pharmacology biopharmaceutics review(s) (Drugs@FDA)
        • 7Orig 1s000 TOC.cfm>. Accessed
        ERLEADA) labeling and multi-discipline review/summary, clinical, non-clinical (Drugs@FDA)
          ...
          1
          2
          ...